Mutual of America Capital Management’s Coherus Oncology CHRS Stock Holding History

Mutual of America Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-13,059	Closed	-$55.8K	–	1450
2023 Q2	$55.8K	Sell	13,059 -234	-2%	-$1.38K	﹤0.01%	1466
2023 Q1	$90.9K	Sell	13,293 -236	-2%	-$1.83K	﹤0.01%	1450
2022 Q4	$107K	Buy	13,529 +694	+5%	+$5.34K	﹤0.01%	1430
2022 Q3	$123K	Buy	12,835 +2,042	+19%	+$20.7K	﹤0.01%	1482
2022 Q2	$78K	Sell	10,793 -162,822	-94%	-$1.42M	﹤0.01%	1553
2022 Q1	$2.24M	Buy	173,615 +40,373	+30%	+$513K	0.02%	914
2021 Q4	$2.13M	Sell	133,242 -923	-0.7%	-$16.1K	0.02%	956
2021 Q3	$2.16M	Sell	134,165 -2,827	-2%	-$41.4K	0.02%	926
2021 Q2	$1.9M	Sell	136,992 -4,560	-3%	-$64.6K	0.02%	988
2021 Q1	$2.07M	Sell	141,552 -6,703	-5%	-$114K	0.02%	950
2020 Q4	$2.58M	Buy	148,255 +51,551	+53%	+$918K	0.03%	803
2020 Q3	$1.77M	Buy	96,704 +93,751	+3,175%	+$1.74M	0.02%	877
2020 Q2	$53K	Buy	+2,953	New	+$50K	﹤0.01%	1324

Other funds holding CHRS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Mutual of America Capital Management's CHRS Position: Q3 2023 in Review

Mutual of America Capital Management sold out of Coherus Oncology (CHRS) in Q3 2023, closing a stake of 13,059 shares — an estimated $55.8K sold.

Mutual of America Capital Management first reported a position in CHRS in Q2 2020 and held it in 13 quarters. The position peaked at $2.58M in Q4 2020. 169 funds tracked by Wall St. Rank hold CHRS as of Q3 2023.

Mutual of America Capital Management reported no remaining Coherus Oncology position as of Q3 2023 after selling out during the quarter.
Mutual of America Capital Management sold 13,059 Coherus Oncology shares in Q3 2023, an estimated $55.8K.
Mutual of America Capital Management first reported a position in Coherus Oncology in Q2 2020 and held it in 13 quarters.
Mutual of America Capital Management's Coherus Oncology position peaked at $2.58M in Q4 2020.
169 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2023.

Based on Mutual of America Capital Management's 13F filing for Q3 2023, filed 9 Nov 2023.